The efficacy and safety of cinacalcet are highly dependent on correct usage and dosage.

Dosage and Administration of Cinacalcet

1. Basic Dosing Principles

(1) Take with or immediately after a meal, swallow the tablet whole.

(2) Tablets must be swallowed whole, do not chew, crush, or split, as this may damage the coating and increase gastrointestinal irritation.

2. Secondary Hyperparathyroidism (Dialysis Patients)

(1) Starting dose: 30 mg once daily.

(2) Dose titration: Increase stepwise every 2-4 weeks to 30, 60, 90, 120, 180 mg once daily, target iPTH level 150-300 pg/mL.

(3) Monitoring points: iPTH levels should be drawn at least 12 hours after dosing. Serum calcium and phosphorus should be rechecked within 1 week after initiation or dose adjustment.

3. Parathyroid Carcinoma or Primary Hyperparathyroidism (Hypercalcemia)

(1) Starting dose: 30 mg twice daily.

(2) Dose titration: Increase stepwise every 2-4 weeks to 30 mg twice daily, 60 mg twice daily, 90 mg twice daily, up to a maximum of 90 mg three to four times daily, aiming to normalize serum calcium.

(3) Maintenance monitoring: Serum calcium every 2 months.

4. Conversion from Other Calcimimetics

When switching from etelcalcetide (Parsabiv) to cinacalcet, discontinue etelcalcetide for at least 4 weeks, confirm serum calcium is not below the lower limit of normal, then initiate cinacalcet at 30 mg once daily.

Medication Precautions

1. Most Important Safety Warning: Hypocalcemia

(1) Before initiating therapy, confirm serum calcium is not below the lower limit of normal.

(2) Cinacalcet can cause life-threatening hypocalcemia, presenting as numbness, muscle cramps, tetany, seizures, QT prolongation, and arrhythmias.

(3) Monitor serum calcium regularly during treatment.

(4) If serum calcium falls below 7.5 mg/dL or symptoms develop, discontinue cinacalcet immediately and seek medical care for calcium supplementation.

(5) Cinacalcet is strictly contraindicated in CKD patients not on dialysis due to very high risk of hypocalcemia (80% of patients in one study had serum calcium<8.4 mg/dL).

2. Gastrointestinal Reactions and Bleeding Risk

(1) Nausea and vomiting occur in approximately 25%-30% of patients, most often during early treatment.

(2) Taking with food may reduce symptoms. Patients with a history of gastritis or ulcer have an increased risk of upper gastrointestinal bleeding. Watch for signs such as black stools or hematemesis; if they occur, seek immediate medical attention.

3. Patients with Cardiac Dysfunction

Post-marketing surveillance has identified possible hypotension, worsening heart failure, or arrhythmias in patients with cardiac dysfunction, often related to decreased serum calcium. Enhanced monitoring is required.

4. Adynamic Bone Disease

(1) Excessive suppression of iPTH to below 100 pg/mL may induce adynamic bone disease.

(2) When iPTH falls below 150 pg/mL, dose reduction or discontinuation should be considered.

5. Drug Interactions

(1) Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May increase cinacalcet plasma levels by approximately 127%. Dose reduction and enhanced monitoring should be considered.

(2) CYP2D6 substrates (e.g., metoprolol, flecainide, desipramine): Cinacalcet can significantly increase the concentrations of these drugs. Dose adjustment of the substrate may be required when used together.

Healthy Lifestyle for Patients

1. Regular Dosing and Monitoring

(1) Take at the same time each day with a meal. Use an alarm or pillbox to avoid missing doses.

(2) Regularly check serum calcium, phosphorus, and iPTH. During maintenance, monitor monthly (for secondary hyperparathyroidism) or every two months (for other indications).

2. Dietary Compliance

(1) Ensure adequate calcium and vitamin D intake (specific regimen as advised by physician).

(2) Avoid excessive consumption of caffeinated or carbonated beverages, as they may affect calcium balance.

(3) A normal meal taken with the medication is sufficient; no need for intentionally high-fat or low-fat diet.